These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21131943)

  • 1. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
    Kenny PR; Brady DE; Torres DM; Ragozzino L; Chalasani N; Harrison SA
    Am J Gastroenterol; 2010 Dec; 105(12):2707-9. PubMed ID: 21131943
    [No Abstract]   [Full Text] [Related]  

  • 2. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ
    Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM; Garrison LP; Wintle M; Blickensderfer A; Wade R; Hou L; Miller LA; Scism-Bacon J; Zagar A; Misurski D; Herman WH
    Curr Med Res Opin; 2011 Mar; 27(3):531-40. PubMed ID: 21219119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Byetta update: what we've learned from experience.
    Cornell S; Todd T
    Diabetes Self Manag; 2010; 27(2):28, 30-1. PubMed ID: 20405747
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecule of the month. Exenatide.
    Drug News Perspect; 2003 Nov; 16(9):621. PubMed ID: 14702143
    [No Abstract]   [Full Text] [Related]  

  • 13. [Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):86-9. PubMed ID: 16550880
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes quiz. How much do you know about Byetta?
    Flannery L
    Diabetes Self Manag; 2007; 24(4):52, 54. PubMed ID: 17663084
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of exenatide for weight loss in patients with diabetes.
    Virji A
    Am Fam Physician; 2007 May; 75(9):1304. PubMed ID: 17511061
    [No Abstract]   [Full Text] [Related]  

  • 17. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 18. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 19. Exenatide and acute pancreatitis.
    Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
    J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide for type 2 diabetes.
    Garattini S; Bertele' V; Floriani I; Torri V
    Lancet; 2009 Jan; 373(9658):122; author reply 122-3. PubMed ID: 19135608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.